Health Advance Inc (OTCMKTS:HADV) has been ripping on a sudden influx of interest following confirmation of the Company’s intention to enter into a definitive merger agreement by October 15 that will leave HADV in control of 99% of JT Hantian LLC, an emerging global leader in anti-aging and vitality nutraceutical products.
Given that the projected global value of the anti-aging market is somewhere between $275 bln and $290 bln by some estimates, the news of the currently non-binding agreement is obviously sparking some interest in HADV shares.
Health Advance Inc (OTCMKTS:HADV) is in the process of ingesting Hantian Labs in a process where the surviving principal business operations will be Hantian’s.
Hantian is an emerging global leader in anti-aging and vitality nutraceutical products. Developed by a team of research scientists, athletes and beauty professionals, the Hantian line of tablets uses state-of-the-art age reversal technology to diminish the signs of aging, whilst enhancing, enriching and extending the lives of their consumers.
Products, including GHBurn, Alpha Elite and Revitamar, are made at Hantian’s GMP ISO 9001 and Informed Sports certified facility in the United Kingdom with the strictest quality standards. Hantian products are Medicines & Healthcare Products Regulatory Agency (MHRA) approved. Hantian also has licenses issued by the Minister of Health for Canada, issued under the authority of section 7 of the Natural Health Products Regulations, for its products GHBurn and Alpha Elite.
Find out when $HADV reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
So far, Health Advance’s move at this point is a non-binding Letter of Intent to acquire 100% interest in Hantian Labs Limited, a private UK corporation .
The acquisition is subject to due diligence by both parties, and the negotiation and execution of a definitive agreement. The agreement will be subject to certain conditions including HADV issuing 15,000,000 shares of the Company in exchange for all the issued and outstanding shares in Hantian.
The Company expects to enter into a Definitive Agreement by October 15, 2016. Once completed, HADV will also control 99% of JT Hantian LLC which represents the revenue arm of Hantian Labs. Currently, JT Hantian has sales in excess of $1,000,000 within the calendar year. “This is a very exciting time for Hantian and we are looking forward to expanding our product line in the coming months. Due to an aging global population, the desire to preserve youth, and the numerous advancements made in reversing the natural process of aging, the world market for anti-aging products is growing at a rapid rate. The need to stay young is a vortex that’s attracting younger consumers and this expansion in target audience is expected to help drive the markets growth into the future,” stated Managing Director, Christian Diesveld.
On closing, Hantian Labs will be held as a subsidiary of Health Advance. The Company believes the acquisition of Hantian will create additional value for Health Advance shareholders. Jordan Starkman, CEO of Health Advance, stated, “We are particularly enthused by the prospects and future growth of Hantian, and are excited to begin our advancement and expansion into the nutraceutical space.”
Nutraceuticals are gaining popularity globally for their ability to prevent and fight several common diseases. In addition to this, they also aid in maintaining a youthful appearance and slowing down the aging process. That’s why we are talking about a market worth upwards of $300 bln.
This shouldn’t be hard to believe. The baby boomer generation was, until the millennials, the largest and wealthiest generation in US history. That demographic group has driven the economic ”shape” of US industry at each stage of their lives. Now that they are in or entering retirement, it should come as no surprise that the market segments most proximal to that stage of life are going to grow in importance.
At this time, carrying a capital value in the market of $4.8M, HADV is setting up for a major transition. The addition of Hantian’s operations and numbers will be a clear boon for HADV shareholders, so it’s no wonder we are seeing such a strong influx of interest in the wake of the announcement of their non-binding agreement. There are still some critical due diligence steps to work through, as the deal is not binding as of yet and could fall through. We will be checking back on the situation soon, and will update it accordingly. For continuing coverage on $HADV and our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!